Legend Biotech Acquires Electroporation Technology License for Cell-Based Therapies from MaxCyte

MaxCyte has granted Legend Biotech a non-exclusive worldwide license to utilize MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for the research, clinical development, and commercialization of cell-based therapeutic products. In exchange, MaxCyte will receive annual licensing fees and milestones during clinical development and, upon successful commercialization, will also be entitled to licensing fees and royalties on net sales of licensed products.

Maher Masoud, president and CEO of MaxCyte, expressed excitement about supporting Legend Biotech’s non-viral engineered cell therapy program and their expansion into new delivery modalities. He highlighted MaxCyte’s global infrastructure, which enables the provision of technical, scientific, and regulatory support to advance Legend Biotech’s non-viral engineered therapeutic pipeline across all major regions.

Ying Huang, PhD, CEO of Legend Biotech, noted that MaxCyte’s clinical manufacturing platform, non-viral cell engineering technology, and regulatory expertise will be instrumental in supporting the development of their product pipeline across various cell types and modalities. He emphasized their goal of transforming the treatment landscape by creating a robust portfolio of cell therapies to enhance patients’ immune systems and combat disease.